Skip to main content

Find Clinical Trials

Home
Conditions
Poorly Differentiated Malignant Neuroendocrine Carcinoma

Clinical trial condition

Poorly Differentiated Malignant Neuroendocrine Carcinoma

Explore clinical trials studying Poorly Differentiated Malignant Neuroendocrine Carcinoma. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Poorly Differentiated Malignant Neuroendocrine Carcinoma trial results

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

NCT02113800

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +20 more
Locations: Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Campus Virchow-Klinikum Berlin, Germany

View Trial Details